Gary R. Lichtenstein, MD
Professor of Medicine (Gastroenterology) at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
3400 Civic Center Boulevard
753 Perelman Center for Advanced Medicine
South Pavilion
Philadelphia, PA 19104
753 Perelman Center for Advanced Medicine
South Pavilion
Philadelphia, PA 19104
Office: 215-349-8222
Fax: 215-349-5915
Fax: 215-349-5915
Publications
Education:
BA (Chemistry)
University of Pennsylvania, 1980.
MD
Mount Sinai School of Medicine, 1984.
Permanent linkBA (Chemistry)
University of Pennsylvania, 1980.
MD
Mount Sinai School of Medicine, 1984.
Description of Research Expertise
My research focuses on inflammatory bowel disease specifically Crohn's disease and Ulcerative Colitis. My particular focuses include1.) medical therapy of inflammatory bowel disease,
2.) safety of current medical therapy for IBD, and
3.) natural history of disease
Description of Clinical Expertise
Inflammatory Bowel DiseaseCrohn's Disease
Ulcerative Colitis
Selected Publications
ASGE IBD Endoscopy Consensus Panel; Shen B, Abreu MT, Cohen ER, Farraye FA, Fischer M, Feuerstadt P, Kapur S, Ko HM, Kochhar GS, Liu X, Mahadevan U, McBride DL, Navaneethan U, Regueiro M, Ritter T, Sharma P, Lichtenstein GR. : Endoscopic diagnosis and management of adult inflammatory bowel disease: a consensus document from the American Society for Gastrointestinal Endoscopy IBD Endoscopy Consensus Panel. Gastrointest Endosc. 2024 Oct 18:S0016-5107(24)03472-2. doi: 10.1016/j.gie.2024.08.034. Epub ahead of print. PMID: 39425706. June 2024.Weber AT, Lichtenstein GR. : Evidence-Based Approach to Chronic Antibiotic Refractory Pouchitis: A Review. Dis Colon Rectum. 2024 Jun 1;67(S1):S99-S105. doi: 10.1097/DCR.0000000000003207. Epub 2024 Feb 16. PMID: 38363696. June 2024.
Lichtenstein GR, Soonasra A, Latymer M, Singh S, Feagan BG. : Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease. Expert Opin Biol Ther. 2024 Jul;24(7):691-708. doi: 10.1080/14712598.2024.2378090. Epub 2024 Jul 18. PMID: 38979696. June 2024.
David T. Rubin, Jessica R. Allegretti, Julián Panés, Nicole Shipitofsky, Shadi Yarandi, Kuan-Hsiang G. Huang ∙ Matthew Germinaro ∙ Rebbecca Wilson ∙ Hongyan Zhang ∙ Brian G. Feagan Tadakazu Hisamatsu ∙ Gary R. Lichtenstein, Brian Bressler, Laurent Peyrin-Biroulet, Bruce E. Sands, Axel Dignass. : The efficacy and safety of guselkumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 quasar maintenance study. Oral Presentation 759. Gastroenterology. AGA AbstractsVolume 166, Issue 5, Supplement S-180 May 18, 2024 May 2024.
Lichtenstein GR. : Exploring Diets Beyond the Low-FODMAP Diet to Treat Patients With IBS. Gastroenterol Hepatol (N Y). 2024 May;20(5):255. PMID: 39193073; PMCID: PMC11345992. May 2024.
Sehgal, Priya∙ Faten Aberra ∙ Tushar Khanna ∙ Klea Profka ∙ Octavia Pickett-Blakely ∙ Neilanjan Nandi ∙ Farzana Rashid Hossain ∙ Meenakshi Bewtra ∙ James D. Lewis ∙ Gary R. Lichtenstein : Safety and clinical effectiveness of glp1 agonists in inflammatory bowel disease patients. Gastroenterology,2024; Volume 166, Issue 5, S-173 - S-174. 721 May 2024.
Marla C. Dubinsky, Milena Gianfrancesco, Genevieve Gauthier, Lara Fallon, Gary R. Lichtenstein, Nabeel H. Khan, Gil Melmed, Stephen B. Hanauer, Timothy Ritter, Griffith Bell, Yi-Chien Lee, Nicole Kulisek, Arne Yndestad, David T. Rubin. : Assessment of steroid use in patients with active ulcerative colitis who initiated a new janus kinase inhibitor or tumor necrosis factor inhibitor using data from a United States claims database. Gastroenterology, Volume 166, Issue 5, Supplement, 2024,Pages S-823-S-824. Su1809. ISSN 0016-5085, May 2024.
Julián Panés, Axel Dignass, Gary R. Lichtenstein, Kuan-Hsiang G. Huang, Matthew Germinaro, Nicole Houck, Chenglong Han, Ye Miao, Hongyan Zhang, Niazy A. Abu Farsakh, Bhaktasharan Patel, Danuta Owczarek, Tadakazu Hisamatsu, Bruce E. Sands, Brian Bressler. : Guselkumab improves health-related quality of life as measured by promis-29 in patients with moderately to severely active ulcerative colitis: phase 3 QUASAR induction study. Gastroenterology, 2024; Volume 166, Issue 5, S-848. Su 1860 May 2024.
Priya Sehgal, Gary R. Lichtenstein, Tushar Khanna, Klea Profka, Octavia Pickett-Blakely, Neilanjan Nandi, Farzana Rashid Hossain, Meenakshi Bewtra, James D. Lewis, Faten Aberra. : Impact of glp1 agonists on inflammatory biomarkers in patients with inflammatory bowel disease. Gastroenterology, 2024; Volume 166, Issue 5, S-591. Sa1950 May 2024.
Lichtenstein GR. : Exploring Cardiovascular Comorbidities and Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2024 Apr;20(4):196. PMID: 38682124; PMCID: PMC11047150. April 2024.